TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00997178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse

Intervention type: OTHER
Group type: OTHER
Intervention: Delayed non-surgical periodontal therapy
Description: Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
Study: NCT03558451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex intervention in sexual health
Description: EXIMe is a complex intervention in sexual health, individualized, in the midwife consultation, where techniques for expression, analysis, information and development of sexual health skills will be used.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: According to available protocols applicable to the patient and the health service standardized portfolio

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: According to available protocols applicable to the patient and the health service standardized portfolio
Study: NCT04217083

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sampling
Description: The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath sampling
Description: The alveolar fraction of Colorectal cancer patients and Healthy controls will be sampled using a breath sampler able to fix the volatile organic compound on absorbable tubes
Study: NCT01428999

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: probiotics 1 pack (2g) bid for three weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: probiotics 1 pack (2g) bid for three weeks
Study: NCT04157647

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: The hemadsorption filter will be included in the CPB circuit between the oxygenator and the venous reservoir. After cardiac surgery, the use of the filter will be continued till 24 hours after the end of surgery.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: No hemadsorption filter or other treatment will be included in the CPB circuit
Study: NCT01671956

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bertilimumab
Description: IV infusion over 30 minutes, at Day 0, Day 14 and Day 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
Study: NCT02999880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polychromatic layering
Description: Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
Study: NCT01305213

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosbretabulin Tromethamine
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01868776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buffered lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nonbuffered lidocaine
Study: NCT00729326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: oral administration (100mg), once a day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: subcutaneous injection (5mcg or 10mcg), twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration (100mg), once a day in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral administration (100mg), once a day in the morning
Study: NCT04468334

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LARIAT + PVI
Description: LAA ligation with the LARIAT System initially performed followed by adjunctive PVI catheter ablation (RF or cryoballoon) in staged procedures
Study: NCT03247413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg/ml
Description: dexamethasone 4 milligram given post-ablation at each lesion site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo, normal saline administered post-ablation at each lesion site
Study: NCT01606735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: dexamethasone
Study: NCT04503928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphorbia kansui Pill
Description: 1 g (10 pills) of Euphorbia kansui Pill taken by mouth, once a day for 7 consecutive days.
Study: NCT01762306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac Potassium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Study: NCT03008733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound UHF peripheral nerves
Description: Ultrasound UHF peripheral nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves
Study: NCT05333484

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programed Pilates
Description: The 60 min Pilates sessions were held twice a week for 12 weeks. Each session included three stages: 10 min of warm-up exercises, 40 min of floor-based Pilates training, and 10 min of cool-down exercises. Each stage was adjusted according to the participants' physical capacity. Only participants with an attendance rate of \> 80% were included in the final sample. The content of the exercise program was determined according to their muscular strength, flexibility, and fitness levels. The training course was divided into three levels: elementary, intermediate, and advanced. Each motion was performed in conjunction with a specific breathing pattern for effective muscle activations of each exercise.
Study: NCT00888459

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine replacement therapy
Description: 4 mg nicotine lozenges, ad lib, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo NRT
Description: Placebo nicotine lozenges
Study: NCT03431974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LD-Aminopterin oral capsule
Description: anti-folate treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
Study: NCT03322384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: Epacadostat will be administered orally, in pill form, twice daily until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
Study: NCT03566264

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT02337140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker SORIN Group KORA DR

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcatheter aortic valve implantation (TAVI)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve implantation (TAVI)
Study: NCT00441350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OM 40
Description: Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OM/HCTZ 40/12.5
Description: Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
Study: NCT01772264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05089771
Description: titration from 150mg BID to 450mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matched placebo
Study: NCT01687348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine aguettant
Study: NCT01660464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT Based Self-help Workbook + Counseling Telepho
Description: Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
Study: NCT02138136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules for oral administration
Study: NCT02563717

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece used for respiratory support (several manufacturers)
Description: Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Study: NCT03008733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electro myography surface nerves
Description: Electro myography surface nerves
Study: NCT01002053

Intervention type: PROCEDURE
Intervention: Nerve conduction study and Ultrasound of the PTN
Description: Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
Study: NCT01925651

Intervention type: RADIATION
Group type: OTHER
Intervention: No Bolus
Description: no bolus use

Intervention type: RADIATION
Group type: OTHER
Intervention: Alternate Bolus
Description: 0.5cm bolus use in alternate days

Intervention type: RADIATION
Group type: OTHER
Intervention: Alternate Bolus
Description: 0.5cm bolus use in alternate days

Intervention type: RADIATION
Group type: OTHER
Intervention: Continuous Bolus
Description: 0.5 cm bolus use in continuous days
Study: NCT00804375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX
Description: cutaneous solution to be applied twice daily for 84 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cutaneous solution to be applied twice daily for 84 days
Study: NCT02767856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IO-therapy Glasses

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IO-therapy Glasses
Study: NCT04799184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25% with epinephrine 5 ug/ml
Description: The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% with epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0.25% without epinephrine 5 ug/ml
Description: The block will be performed under ultrasound vision at T5 level, with the patient seated.~Once the ultrasound image is achieved, a 100 mm, 20 G Stimuplex needle will be punctured and a solution of levobupivacaine 0.25% without epinephrine 5 ug / ml until completing a volume of 20 ml in fractional form.
Study: NCT02097433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
Study: NCT02892838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile bearing knee system for total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed bearing total knee prosthesis
Study: NCT03537352

Intervention type: PROCEDURE
Intervention: Any appropriate surgical treatment
Description: Any appropriate surgical treatment for the management of patient's current disorder

Intervention type: DRUG
Intervention: Any appropriate drug or non-drug treatment excluding surgery
Description: Any appropriate drug or non-drug treatment excluding surgery for the management of patient's current disorder
Study: NCT01326117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: 7 days of Cialis for Daily Use (5mg)
Study: NCT01608399

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
Study: NCT01365377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: booklet deliverance and use in the process of daily information
Description: The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
Study: NCT01464788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Argatroban
Description: 100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Argatroban
Description: 100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA (alteplase)
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA (alteplase)
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA (alteplase)
Description: rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
Study: NCT03831308

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical and physical assessment
Description: information will be collected on fitness status, lifestyle, cognitive and psychological status, bone's health and quality of life
Study: NCT01811355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: Sodium channel blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05239377

Intervention type: OTHER
Intervention: IntelliSpace Precision Medicine Multidisciplinary Team Orchestrator
Description: Digital decision support
Study: NCT02557412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive lifestyle intervention
Description: Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% \[saturated fats \<7% monounsaturated fats up to 20% and polyunsaturated fats \<10% \] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional treatment
Description: Hygiene and diet recommendations on sleep
Study: NCT00218920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: continuous moderate-intensity aerobic training
Description: The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval aerobic training
Description: High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax \[maximal HR (heart rate)\], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
Study: NCT02558556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Fluorescence Imaging System (Karl Storz)
Description: The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
Study: NCT01736254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evacetrapib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Study: NCT04172753

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy on the MR-Linac
Description: Radiotherapy is performed on the 1.5 T MR Linac
Study: NCT04134793

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: bipolar radiofrequency ablation by ablation forceps

Intervention type: PROCEDURE
Intervention: radiofrequency ablation
Description: bipolar radiofrequency ablation by ablation forceps
Study: NCT02543125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NHFOV
Description: For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician.
Study: NCT02563717

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New system used for respiratory support
Description: Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
Study: NCT01311557

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Description: 0.5 mL, Intramuscular
Study: NCT02104336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-743
Description: EPI-743 is the quinone oxidation product of alpha-tocotrienol